Whether its activity is lost by mutation, deletion, or promoter methylation silencing at high frequency, as is the case in many primary and metastatic human cancers, PTEN downregulation usually has the same result: persistent AKT signaling that contributes to tumor formation [28, 29]. This evidence concerns the gene AKT1 and neoplasm.